The ability of memory T cells to mount a recall response plays a key role in the ability of vaccinated animals to contain viral challenge. In this study, we intensively monitored the expansion of SIV Gag-specific CD8+ T cells in peripheral blood and tissues of rhesus macaques vaccinated with the attenuated strain SIVmac239D3 and challenged with the pathogenic viruses SIVmac239 or SIVsmE660. Although all vaccinated animals were infected with challenge virus, peak levels of plasma viremia in vaccinees were decreased by 1.5 to 2 logs as compared with naive controls. Decreased levels of plasma viremia in vaccinated animals were evident as early as 7 days post-challenge, well before the expansion of SIV-specific CD8+ T cells. Expansion of SIV-specific CD8+ T cells was not observed in peripheral blood or tissues until at least 14 days after infection and did not occur in most animals until after the initial peak of viral replication. The observation that expansion of SIV-specific CD8+ T cells is delayed until 7 days or more after initial detection of viremia highlights fundamental limitations in the ability of lentivirus-specific CD8+ T cells to mediate protection against challenge. D Virology 333 (2005) 226 -238 www.elsevier.com/locate/yviro U.M. Abdel-Motal et al. / Virology 333 (2005) 226-238
Introduction
Infection with viral pathogens characteristically results in a rapid expansion of virus-specific CD8+ T cells, which in many settings play a central role in containing viral replication. In vaccinated or previously infected animals, this expansion phase typically occurs more rapidly and results in higher peak levels of virus-specific CD8+ T cells than in naive animals, although in the absence of neutralizing antibody responses, cytotoxic T lymphocyte (CTL) responses do not generally provide sterile protection (Ahmed and Gray, 1996; Doherty and Christensen, 2000) . Nonetheless, the rapid expansion of virus-specific CD8+ T cells can result in prevention of disease induced by many pathogens, including influenza, lymphocytic choriomeningitis virus, cytomegalovirus, and pathogenic lentiviruses such as simian-human immunodeficiency viruses (SHIV) (Del Val et al., 1991; Flynn et al., 1998; Lau et al., 1994; Shiver et al., 2002) . 0042-6822/$ -see front matter D 2005 Elsevier Inc. All rights reserved. doi:10.1016/j. virol.2004.12.030 Vaccination of macaques with attenuated SIV strains has proved to be one of the most effective strategies to induce protection against SIV infection . Attenuated SIV strains defective in nef or other genes have proved highly effective in inducing protection against pathogenic, difficult to neutralize strains such as SIVmac251 and SIVmacJ5 following intravenous, rectal and vaginal challenge (Almond et al., 1995; Connor et al., 1998; Cranage et al., 1997; Daniel et al., 1992; Johnson et al., 1999) . Despite intensive study, the mechanisms by which attenuated SIV strains induce protection against challenge remain poorly understood. Most attenuated SIV strains induce relatively potent SIV-specific antibody responses, which have in some studies correlated with protection (Cole et al., 1997 (Cole et al., , 1998 Johnson et al., 1999; Wyand et al., 1996) . Infection with attenuated strains such as SIVmac239Dnef or SIVmac239D3 also induces a diverse array of cellular immune responses, including SIV-specific CTL responses (Dittmer et al., 1995; Johnson et al., 1999; Lohman et al., 1994) and proliferative responses (Dittmer et al., 1995; Gauduin et al., 1999) , as well as CD8+ T cell-mediated production of h-chemokines and other soluble factors able to inhibit SIV replication (Gauduin et al., 1998) . Evidence for a role of SIV-specific CTL in mediating protection induced by attenuated lentiviruses is indirect, but includes correlations in some studies of CTL activity with protection Miller et al., 1997; Quesada-Rolander et al., 1996) and the fact that protection can be mediated independently of neutralizing antibodies (Gundlach et al., 1998; Johnson et al., 1999; Shibata et al., 1997) . However, the precise role that SIVspecific CD8+ T lymphocytes play in mediating protection induced by attenuated SIV remains a matter of debate.
As one approach to better understand the role of SIVspecific CD8+ T cells in mediating protection induced by attenuated SIV, we undertook a study to examine the early kinetics of SIV-specific CD8+ T lymphocyte responses in macaques vaccinated with SIVmac239D3 and subsequently challenged with either with a homologous (SIVmac239) or heterologous (SIVsmE660) SIV strain. Based on prior results documenting sterile protection against SIVmac251 (Wyand et al., 1996) and less complete protection against the heterologous uncloned, pathogenic isolate SIVsmE660 in SIVmac239D3-vaccinated animals, we hypothesized that intensive analysis of SIV-specific CD8+ T cell responses in the early stages of successful and unsuccessful pathogenic challenge might yield insights into the kinetics of SIV-specific CD8+ T cell recall responses and to whether SIV-specific CTL play a role in containing the initial peak of viral replication. Because the dominant sites of early SIV replication are in gut-associated lymphoid tissue and lymph nodes (Veazey et al., 1998) , we carried out multiple serial biopsies of these sites in the first 2 weeks after challenge, utilizing MHC class I tetramers to precisely quantitate the frequency of SIV-specific CD8+ T cells. Although sterile protection was not observed, SIVmac239D3 vaccinated animals contained viral replication of both Fig. 1 . SIV plasma RNA levels after challenge of naive and vaccinated animals. Naive animals and SIVmac239D3 vaccinated animals were challenged intravenously with either SIVmac239 or SIVsmE660. SIV plasma RNA levels were quantitated by bDNA assays as previously described (Sodora et al., 1998) . The lower limit of detection was 400 copy equivalents (ceq) per ml of plasma. challenge viruses with significantly lower peak and set point viral loads than naive controls. The fact that detectable levels of SIV Gag-tetramer binding cells were present in vaccinated animals prior to challenge allowed us to precisely time the point at which SIV-specific CD8+ T cells began to expand after challenge, an examination which has not been possible in many prior studies of vaccinated animals post-challenge. Expansion of SIV-specific CD8+ T cells was not observed in peripheral blood or tissues until at least 14 days after infection, and did not occur in most animals until after the initial peak of viral replication.
Results

Decreased peak and set point plasma viremia in SIVmac239D3 vaccinated macaques
The vaccinated animals used in this study had all been infected intravenously with SIVmac239D3 as neonates as previously reported . Three animals developed sustained SIV-specific antibody responses, while the fourth (61-95) developed only transient low-level antibody responses to SIV and then seroreverted after 16 weeks . Vaccine virus was never recovered from PBMC cultures of animal 61-95, although it was recovered from each of the 3 other vaccinated animals in the first 5 months after infection. All 3 persistently SIVmac239D3-infected animals remained healthy prior to challenge, with normal CD4+ T cell counts and undetectable plasma SIV viral RNA loads (b400 copies/ml). Naive and vaccinated animals were then challenged intravenously, in groups of 2, with either SIVmac239 or SIVsmE660, approximately 62 months after initial SIVmac239D3 vaccination. Based on the lack of vaccine virus recovery and the lack of detectable SIVspecific antibody or cellular immune responses (see below) prior to challenge, we excluded the seroreverting animal 61-95 from analysis of viral loads after challenge in vaccinees compared with controls. All naive and vaccinated animals were infected after SIVmac239 or SIVsmE660 challenge. By day 8 post-challenge, mean plasma viral RNA levels in naive animals were over 3 logs higher (mean of log transformed viral load 5.6 Â 10 6 copies/ml) than in the 3 persistently infected SIVmac239D3-vaccinated animals (mean 1.8 Â 10 3 copies/ml) ( P b 0.05, Mann-Whitney U test). Peak levels of plasma viremia at days 10 to 21 in the 3 vaccinated animals were decreased by 1.5 to 2 logs as compared with naive controls ( P b 0.05) (Fig. 1) , and levels of plasma viremia at 42 days post-infection were decreased by 2 to 3 logs ( P b 0.05), subsequently falling to undetectable levels in 2 animals. The data suggest that in contrast to the control monkeys, the vaccinated animals were better able to control SIV infection, with 2 of 3 persistently infected vaccinated animals achieving transiently undetectable plasma levels of virus, which was sustained to day 154 in one animal (905-95).
Kinetics of SIV Gag 181-189 -specific responses in peripheral blood, lymph nodes, and rectal biopsies following challenge SIV-specific CD8+ T cell responses were monitored in peripheral blood, lymph node, and rectal biopsies using a tetrameric complex of the rhesus Mamu A*01 molecule with an immunodominant Gag epitope correspond- ing to amino acids 181-189 (Allen et al., 1998) . All 4 SIVmac239D3-vaccinated animals and one naive control (79D-248) expressed the Mamu-A*01 allele. Prior to challenge, 3 of 4 SIVmac239D3 vaccinated animals had detectable Mamu-A*01/Gag 181-189 tetramer-binding cells in whole blood, comprising 0.1% to 0.9% of all circulating CD8+ T lymphocytes (Fig. 2, Tables 1 and 2) . The SIVmac239D3-vaccinated animal (61-95) that had seroreverted and remained antibody negative had undetectable levels of SIV Gag 181-189 tetramer-binding cells in peripheral blood and lymph node (Table 2) prior to challenge. As expected, the naive Mamu-A*01-positive animal prior to infection and all Mamu-A*01-negative animals had undetectable levels (b0.1%) of Mamu-A*01/Gag 181-189 tetramerbinding cells (Fig. 2 , Tables 1 and 2). Since lymphoid tissue and gut-associated lymphoid tissue are the dominant sites of replication after acute SIV infection (Veazey et al., 1998) , we also examined the frequency of SIV Gag-tetramer binding cells in these compartments. Although levels varied from animal to animal, levels of SIV Gag 181-189 specific cells were generally higher in lymph nodes or rectal biopsies than in whole blood (Tables 1 and 2) . Remarkably, despite the fact that SIV plasma RNA levels were first detectable at day 8 and exceeded 10 4 copies/ml in 2 of 3 persistently infected vaccinated animals by 10 days after challenge, an increase in the frequency of tetramer-binding cells in peripheral blood of vaccinated animals was first detected at day 14 only in a single animal (82-95), the same point at which a significant percentage of SIV Gag-specific T cells were first observed in the naive Mamu-A*01-positive control (97D-248) infected with SIVmac239 (Table 1) . Increases above baseline in the frequency of SIV Gag tetramer-binding cells in peripheral blood of the 2 other SIVmac239D3 persistently infected animals (60-95 and 905-95) were not detected until day 21. Identical kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes were observed when frequencies were calculated as the absolute number of SIV Gag 181-189 tetramer binding cells per Al whole blood (data not shown). Similarly, no increase in the frequency of Mamu-A*01-positive Gag 181-189 tetramer-binding cells was observed in lymph nodes 8 days post-challenge in either of the 2 vaccinated animals for which results were available, and only 1 of 3 animals showed an increase in SIV Gag-specific T cells in lymph node at day 14 (Tables 1 and 2). Analysis of rectal biopsies in persistently infected vaccinated animals at day 14 after challenge revealed a clear increase in the frequency of Fig. 3 . SIV-specific ELISPOT responses. Production of IFN-g was assayed after 48 h stimulation of PBMC with recombinant vaccinia expressing SIV Gag or Env. The frequency of SIV specific spots forming cells (SFC) was determined by subtracting the mean number of background spots obtained with the control vaccinia virus NYCBH from the number obtained with the SIV-expressing vaccinia. Animals challenged with SIVmac239 were tested using SIVmac251 Gag or SIVmac239 Env; animals challenged with SIVsmE660 were tested using SIVsmH4 Gag/Pol or Env. nd = not done.
Mamu-A*01/Gag 181-189 tetramer-binding cells only in animals 82-95, which also exhibited an increase in tetramerbinding cells in peripheral blood at that time point. By day 21 after challenge, significant increases in the levels of Mamu-A*01/Gag 181-189 tetramer-binding CD8+ T cells were observed in all vaccinated animals, with peak levels rising to as much as 18% of circulating CD8+ T cells (Table 1 and Fig. 2 ). In contrast, in the Mamu-A*01-positive naive animal, the level of Mamu-A*01/Gag 181-189 tetramer-binding CD8+ T cells was lower (1% to 4% of circulating CD8+ T cells), a level consistent with previous reports in naive animals after SIV infection (Kuroda et al., 1999) . Thus, in all vaccinated animals, significant increases in the frequency of SIV-specific CD8+ T cells were not detected until 14 to 21 days after infection, at least 1 week after the initial detection of plasma viremia.
SIV-specific ELISPOT responses after challenge
PBMC from vaccinated and non-vaccinated animals were isolated at different time points after challenge with SIVmac239 or SIVsmE660 and production of IFN-g following stimulation with SIV Gag or Env was examined using ELISPOT assays. Prior to challenge, the 3 persistently SIVmac239D3-infected animals had levels of SIV Gag-specific spot forming cells (SFC) between 122 and 216 per 10 6 PBMC, while no significant responses (b50 SFC/10 6 PBMC) were observed in the seroreverting animal 61-95 or the naive controls ( Fig. 3) . Following SIVmac239 challenge, the SIVmac239D3-vac-cinated animal 82-95 exhibited high levels of Gagspecific SFC at days 14 and 42 post-challenge (2700 and 3300 SFC/10 6 PBMC) ( Fig. 3) , consistent with the strong responses observed using the SIV Gag 181-189 tetramer and CTL assays. Monkey 60-95, in contrast, had lower levels of Gag-specific SFC (170-603 SFC/10 6 PBMC) at all time points (Fig. 3) . Notably, although animal 60-95 had only a low level of Gag SFC, this animal had a one log lower viral load than animal 82-95 by day 42 after challenge. The persistently infected SIVmac239D3 animal (905-95) challenged with SIVsmE660, which had excellent control of viremia after challenge, maintained relatively high levels of Gag-specific SFC at days 7 to 28 post-challenge (517 to 977 SFC per 10 6 PBMC). The seroreverting animal (61-95) never developed significant levels of Gag/Pol-specific SFC at any time point after challenge (Fig. 3 ). In naive animals challenged with SIVmac239, Gag-specific ELISPOT responses varied between 98 and 650 SFC/10 6 PBMC after challenge, whereas no detectable SIV Gag-specific SFC were observed in the 2 naive animals challenged with SIVsmE660 ( Fig. 3 ). Levels of Env-specific SFC were generally lower than observed for Gag, and when observed (e.g., animal 905-95), displayed similar kinetics as Gagspecific SFC (Fig. 3) .
SIV-specific CTL responses after challenge
To complement the data obtained using MHC class I tetramers and ELISPOT assays, we analyzed SIV-specific Fig. 4 . Gag-specific CTL activity following SIV challenge. CTL activity was determined in standard Cr 51 -release assay at multiple effector to target ratios (E/ T); representative data for an E: T of a 40:1 are shown. Levels of lysis of control vaccinia-infected B-LCL ranged between 0 and 6%. CTL responses in peripheral blood following in vitro antigen-specific stimulation. CTL responses against SIV Gag were prospectively evaluated before and after challenge with fresh PBMC stimulated with autologous B-LCL infected with recombinant vaccinia viruses expressing SIV proteins, as described previously (Johnson et al., 1997) . Although results varied between assays, all vaccinated animals except 61-95 (the animal that seroreverted) had detectable SIV-specific CTL activity in at least one of the two pre-challenge assays (Fig. 4) . Consistent with the results obtained using the Mamu-A*01 Gag 181-189 tetramer, SIV-specific CTL activity increased at day 14 postinfection. At later time points, SIV-specific CTL activity continued to increase in the vaccinated animals with the best control of viremia (60-95 and 905-95). Notably, although the highest levels of SIV Gag 181-189 tetramer-binding cells (16%-18%) in peripheral blood were observed in animal 82-95, this animal had approximately 3-fold lower CTL activity at day 42 than animal 60-95, which had an almost 3-fold lower level of Mamu-A*01 Gag 181-189 tetramerbinding cells (Table 1) . All naive animals also had significant levels of SIV-specific CTL on day 14 after infection, which varied thereafter (Fig. 4) . No significant differences in CTL activity were observed in the SIVsmE660 challenged animals using target cells express-ing SIV antigens from the SIVsmE660 related strain SIVsm H4 (data not shown).
Analysis of SIV-specific antibody responses
Prior to challenge, all vaccinated animals, except the seroreverting animal 61-95, had detectable levels of antibodies (Table 3) . Following challenge, a dramatic increase in envelope-specific antibody levels was observed starting at day 28 in all 3 persistently infected vaccinated animals, rising to titers of 102,400 to 204,800, consistent with an amnestic response (Table 3 ). In the seroreverting animal 61-95 and the naive controls, SIV envelope-specific antibody responses were detected by day 28 post-challenge in all animals, but were on average 1-2 logs lower than antibody titers observed in the vaccinated animals. No clear difference in antibody titers between SIVmac239 and SIVsmE660 challenged animals was observed ( Table 3) . Examination of neutralizing antibody titers to SIVmac239 and SIVsmE660 prior to and after challenge revealed no significant neutralizing activity to either of these viruses (not shown). Neutralizing antibody titers to T cell line adapted SIVmac251 of between 300 and 1000 were found in the 3 persistently infected SIVmac239D3-infected macaques prior to challenge (Table 4 ). Increases in SIV- mac251 neutralizing antibody titers were first detected at 28 days post-challenge, and at 154 days after challenge ranged from 5200 to 43,740, with no significant difference between vaccinees and naive animals.
Discussion
To better understand the role that SIV-specific CD8+ T lymphocytes may play in protection against challenge, we carried out a detailed analysis of the frequency of SIV Gagspecific CD8+ T cells in peripheral blood and tissues of SIVmac239D3-vaccinated animals after challenge with pathogenic SIV strains. We reasoned that intensive analysis of kinetics of SIV-specific CD8+ T cell responses in the early stages following challenge might yield insights into the role of SIV-specific CD8+ T cells in containing the initial peak of viral replication and set-point levels of viremia. Although sterile protection against either SIVmac239 or SIVsmE660 was not achieved in animals vaccinated with SIVmac239D3, we observed significantly lower peak and set point levels of plasma SIV RNA after infection. Notably, the expansion of SIV-specific CD8+ T cells in vaccinated animals in peripheral blood was delayed until 7 to 14 days after peak viremia, and similar kinetics of expansion were observed in lymph nodes and rectal biopsies.
One of the hallmark characteristics of memory CD8+ T cells is their ability to expand briskly after antigenic stimulation, generally leading to more rapid viral containment (Ahmed and Gray, 1996; Doherty and Christensen, 2000) . The rapid expansion of memory virus-specific CD8+ T cell responses to relatively high frequencies following viral challenge appears to reflect both the increased frequency of virus-specific cells and the more rapid proliferation of memory than naive T cells (Cho et al., 1999; Doherty and Christensen, 2000) . For instance, in mice rechallenged with influenza, increases in the frequency of virus-specific CD8+ T cells can be detected 2 days earlier than in naive animals and subsequently rise to levels approximately 3-fold greater than in naive animals (Flynn et al., 1999) . Several studies analyzing the kinetics of SIVspecific CD8+ T cell responses after intravenous challenge of vaccinated macaques have also revealed a more rapid response than in naive animals, resulting in detectable increases in the frequency of tetramer-binding cells 2 to 4 days earlier than observed in controls (Egan et al., 2000; Seth et al., 2000) . However, in these previous studies (Egan et al., 2000; Seth et al., 2000) , levels of SIV Gag 181-189 tetramer binding cells were generally undetectable at the time of challenge, thus precluding precise determination of the time at which expansion of SIV-specific CD8+ T cells began. In our study, the ability to follow baseline levels of SIV Gag 181-189 tetramer binding cells, which remained unchanged for periods of 10 to 14 days or more after challenge in the immunized animals, demonstrate that expansion of SIV-specific CD8+ T cells is delayed until approximately 7 days after initial detection of plasma viremia. These data are quite similar to those recently reported by Davenport et al. (2004) , who analyzed the kinetics of expansion of Mamu-A*01/Gag 181-189 tetramer-binding cells in vaccinated animals after SHIV-89.6P challenge. Analysis of lymph node biopsies and rectal biopsies in our study revealed similar kinetics of expansion of SIV-specific CD8+ T cells in these sites, suggesting that the failure to detect an increase in tetramer-binding cells in peripheral blood is not due to sequestration of proliferating antigen-specific cells in lymphoid tissues. Although we focused our quantitative analysis of SIV-specific CD8+ T cells on cells able to bind the Mamu-A*01-restricted Gag 181-189 epitope, these data were corroborated by analysis of CTL and ELISPOT responses to Gag and Env in PBMC. Unfortunately, levels of Mamu-A*-01/Tat 28-35 tetramer-binding cells are undetectable in the majority of animals that are chronically infected with SIVmac239D3 (unpublished observations), so we were not able to extend these observations using tetramers other than Mamu-A*01/Gag 181-189 .
Several factors may account for the approximate 7 day delay between the onset of detectable viremia and the detection of Gag-specific CD8+ T cell expansion in vaccinated animals, including delays in antigen processing and presentation of SIV antigens to virus-specific CD8+ T cells, delays in CD8+ T cell expansion following antigenic stimulation, and delays in trafficking of SIV-specific CD8+ T cells from lymphoid tissues to peripheral blood. Incomplete information at present regarding the kinetics of these processes in primates preclude an unequivocal answer to the reason for this delay. In murine models of influenza infection, delays in the expansion of virus-specific CD8+ T cell responses are believed in part to be due to the fact that antigenic stimulation occurs in regional lymph nodes after migration of antigen-presenting cells and memory T cells to these sites (Doherty, 1997; Doherty and Christensen, 2000) . Delays in antigen processing within infected cells appear unlikely to contribute significantly to this delay, since in vitro studies have demonstrated that recognition of HIVinfected CD4+ T cells can occur within approximately 24 h after virus infection, roughly coincident with the detection of virus production (Yang et al., 1996) . Regardless of the precise mechanism, this 7-day delay in essence provides the virus with a head start of 5 to 7 replicative cycles prior to expansion of SIV-specific CD8+ T cells. Although vaccination of animals can increase the frequency of virusspecific CD8+ T cell responses after virus challenge and slightly accelerate the detection of virus-specific CD8+ T cell responses, the limitations inherent in kinetics of CTL expansion may in part explain the failure of vaccine approaches that induce only CTL responses to provide significant protection against SIV challenge (Horton et al., 2002) .
Comparison of pre-challenge and peak levels of tetramer-binding cells prior to challenge in persistently SIVmac239D3-infected animals also allows calculation of the extent of expansion of Gag-specific cells after challenge, which varied between 12-and 30-fold in vaccinated animals. This degree of expansion corresponds to between 3.6 and 4.9 cell division cycles, assuming the loss of dividing cells to apoptosis during this expansion phase is negligible. Recent studies in mice have shown that even a brief contact of naive T cells with antigen results in 7 to 10 rounds of cell division in vitro, suggesting that once triggered, naive T cells enter a preprogrammed phase of proliferation even in the absence of continued antigenic stimulation (Kaech and Ahmed, 2001; van Stipdonk et al., 2001) . A similar magnitude of proliferation corresponding to 128-to 1024-fold expansion of antigen-specific cells with a starting frequency of 0.3% to 0.5% would result in CD8+ T cells specific for a single epitope comprising over 50% of the total body T cell pool and significantly disturb T cell homeostasis. Different mechanisms are therefore likely to control proliferation of memory T cell responses after antigenic stimulation, resulting in lower overall levels of proliferation than for naive cells.
Despite the failure of SIV-specific CD8+ T cells to expand before day 14, levels of plasma viral RNA in persistently infected vaccinees were 2 logs lower than naive animals even as early as day 7 post-challenge. Several possibilities may explain this observation. One possibility is that CTL may be effective in inhibiting SIV replication even without expansion, for example, through production of gchemokines and other soluble factors able to inhibit SIV replication (Gauduin et al., 1998) . Another possibility is inhibition of SIV replication by antibody responses, as suggested by the evidence that many attenuated SIV strains induce relatively potent SIV-specific antibody responses, which have in some studies correlated with protection (Clements et al., 1995; Cole et al., 1997; Johnson et al., 1999; Wyand et al., 1996) . Finally, innate immune responses such as natural killer cells or gamma-delta cells that exert their effects during the early stages of infection before the boosting of adaptive immune responses may also play a role in the early control of viremia (Tenner-Racz et al., 2004) .
While there have been previous reports of induction of sterilizing protection by attenuated SIV against challenge with pathogenic SIV (Almond et al., 1995; Clements et al., 1995; Connor et al., 1998; Cranage et al., 1997; Daniel et al., 1992; Johnson et al., 1999; Wyand et al., 1996) , our results showed that none of the vaccinated animals exhibited sterilizing immunity against SIVmac239 or SIVsmE660 challenge. The failure to observe sterile protection in SIVmac239D3-vaccinated animals may reflect several factors, including: (1) less effective protection induced by the more attenuated strain SIVmac239D3 as compared with SIVmac239Dnef (Connor et al., 1998) ; (2) the use of sensitive plasma SIV RNA assays in place of quantitative viral culture assays, which in previous studies have failed to detect viral replication in some challenged animals with SIV plasma RNA levels as high as 10 5 copies/ ml ; (3) the use of intravenous instead of mucosal challenge, which has previously been reported to result in better protection against more attenuated SIV strains ; and (4) the delay of over 5 years between vaccination and challenge, whereas previous studies examining protective immunity induced by SIVmac239D3 have observed sterile protection following intervals of no more than 1 1/2 years after vaccination Wyand et al., 1996) . Although the fact that SIVmac239D3 can induce immunodeficiency following infection of neonatal macaques with relatively high dose inocula (Baba et al., 1995; Wyand et al., 1997) raises the possibility that neonatal vaccination of macaques with SIVmac239D3 may be less effective at inducing protection against subsequent challenge than vaccination of juvenile or adult macaques, we believe this possibility is unlikely. First, all of the SIVmac239D3 infected macaques reported here exhibited excellent control of attenuated virus replication with no evidence for immunodeficiency. Second, baseline levels of SIV-specific cellular and humoral immune responses prior to challenge were quite similar to those observed in juvenile or adult macaques infected with SIVmac239D3 (Cromwell et al., 2000; Johnson et al., 1999 and unpublished data) . Similar levels of SIV-specific neutralizing antibody responses have been observed in macaques infected with SIVmac239D3 as neonates or adults . Finally, a recent study analyzing SIV plasma viral RNA levels in macaques vaccinated with SIVmac239D3 as juveniles and subsequently challenged intravenously with SIVmac251 also revealed a similar lack of sterile protection as observed in the present study (unpublished data). However, despite the fact that sterile protection was not observed, SIVmac239D3-vaccinated animals efficiently contained viral replication with significantly lower peak and set point viral loads than naive controls.
Defining the early events following virus challenge has important implications for our understanding of mechanisms of protection and control of viremia in vaccinated macaques. Our present results highlight the limitations that virusspecific CD8+ T cells face in protecting the host against challenge with SIV or HIV.
Materials and methods
Animals, virus stocks, immunization, and challenge
Eight rhesus macaques were used in this study. Four of them were naive and the other four had been infected intravenously as neonates with SIVmac239D3 as previously described . All animals were housed in the biocontainment facility at Primedica. Intravenous challenge was carried out with either 10 animal infectious doses SIVmac239 or 100 animal infectious doses of SIVsmE660 as indicated. The preparation, titration, and use of the SIVmac239 and SIVsmE660 challenge stocks have been described previously Goldstein et al., 1994) . The presence of the Mamu-A*01 MHC class I allele was determined using sequence-specific primer PCR as previously described (Knapp et al., 1997) .
Viral load analysis
Quantitation of SIV plasma RNA was performed by bDNA assays as previously described (Chiron/Bayer Diagnostic, Emeryville, CA) (Sodora et al., 1998) . The lower limit of detection of this assay at the time this study was performed was 400 copies per ml.
Cell isolation and mucosal biopsies
Blood for immunologic assays was collected in heparinized CPT Vacutainer tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, and NJ) . Blood for flow cytometry and complete blood counts was anticoagulated with EDTA. Lymph nodes and rectal biopsies were collected in phosphate-buffered saline (PBS). T cells from rectal biopsies were isolated as previously described . Briefly, all rectal biopsies were incubated with 5 mM EDTA for 30 min, washed and incubated with 15 U/ml collagenase (type II, Sigma) followed by mechanical disruption with an 18 gauge-feeding needle. Intestinal lymphocytes were then enriched by bilayer (35%/60%) isotonic Percoll density gradient centrifugation (1000 Â g, 20 min) and the interface containing the lymphocytes was collected. Lymphocytes were isolated from lymph nodes by dissociation of tissue by mincing with scalpel blades and gently pressing tissue fragments through nylon mesh screens. All blood samples and biopsies were shipped within 2-3 h of collection to the New England Primate Research Center. Automated cell counts were performed using a Series 9000 Hematology Series Cell Counter (Serono Baker Diagnostics, Allentown, PA) using cell size discriminators optimized for rhesus macaques. Leukocyte differential counts were performed manually by counting 100 white blood cells on a Wright's stained blood smear.
Flow cytometric analysis
Four-color flow cytometry was used for immunophenotyping of whole blood lymphocytes using standard procedures as previously described (Cromwell et al., 2000) . Briefly, 200 Al of rhesus whole blood in 12 Â 75 mm polystyrene test tube (Falcon, Lincoln Park, NJ) was incubated with the following monoclonal antibodies: 20 Al of FITC-conjugated CD3, (clone SP34), 20 Al of PEconjugated CD4 (Leu-3a), 20 Al of PerCP-conjugated CD8 (Leu-2a), all from BD Biosciences (San Diego, CA). All antibodies were mAbs of anti-human specificity that cross-react with rhesus antigens of the same specificity. Tetramer staining was carried out using 10 Al of allophycocyaninconjugated Mamu-A*01/Gag 181-189 tetramer (Allen et al., 1998) as previously described (Cromwell et al., 2000) . Negative controls consisting of SIV-infected Mamu-A*01negative or uninfected Mamu-A*01-positive animals were included in each flow cytometric analysis. Based on analysis of these negative controls, levels of Mamu-A*01/Gag 181-189 tetramer-binding cells of z0.1% CD8+ T lymphocytes in blood and lymph node and z 0.2% CD8+ T lymphocytes in rectal biopsies were considered significant. Stained cells were fixed in 1% paraformaldehyde and analyzed on a Becton Dickinson Immunocytometry Systems FACSCalibur. In general, a total of 200,000 events were acquired, and analysis of tetramer-binding cells was carried out on CD3+CD8+ gated lymphocytes. For rectal biopsies, the T lymphocyte population was first identified by gating on events based on CD3 expression and forward scatter and analysis was then performed as for whole blood. In some instances, the frequency of tetramer-binding T cells was calculated by pooling results from replicate samples from the same rectal biopsy specimen. Samples were only used for analysis if a distinct tetramer-staining population of CD3+CD8+ cells could be identified.
IFN-c ELISPOT assay
ELISPOT assays for IFN-g-secreting cells were performed with a commercial kit (U-Cytech, Utrecht, The Netherlands), based on a previously published technique adapted for rhesus macaques (Gauduin et al., 1999; van der Meide et al., 1995) . Briefly, ninety-six-well flat-bottom plates were coated with 50 Al/well of anti-IFN-g mAb MD-1 (U-Cytech) overnight at 4 8C. The plates were washed 10 times with PBST (PBS containing 0.05% Tween 20) and blocked with PBS containing 1% BSA for 1 h at 37 8C. Serial dilutions of freshly isolated PBMC (3 Â 10 5 , 1 Â 10 5 and 3 Â 10 4 cells per well) in R10 medium were plated in duplicate, and infected with recombinant vaccinia viruses expressing either SIVmac251 Gag and SIVmac239 envelope (Env) (for SIVmac239 challenged animals), SIVsmH4 Gag/Pol and Env (for SIVsmE660 challenged animals) or the control vaccinia virus NYCBH. After incubation for 48 h at 37 8C in 5% CO 2 nonadherent cells were then removed, and 200 Al/well of ice-cold deionized water was added to lyse the remaining PBMC. Plates were incubated on ice for 15 min and washed 20 times with PBST. One hundred Al per well of anti-IFN-g detector Ab (U-Cytech) was added, and plates were incubated for 1 h at 37 8C before being washed 10 times with PBST. Fifty Al per well of GABA (U-Cytech) was added for 1 h at 37 8C and washed 10 times with PBST. Thirty Al per well of activator mix (U-Cytech) was then added and developed for 30 min to allow formation of silver salt precipitate at the site of gold clusters. Wells were then washed with distilled water and air-dried, and spots were counted with a KS ELISPOT Automated Reader System (Carl Zeiss Inc, Thornwood, NY) using KS ELISPOT 4.2 software (performed by Zellnet, New York, NY). Results are presented as the frequency of SIV-specific spot forming cells (SFC) per 10 6 PBMC minus the frequency of SFC per 10 6 PBMC obtained with NYCBH infection. Calculated frequencies were based on the average of the duplicate wells plated at 3 Â 10 5 and 1 Â 10 5 cells per well; the frequency of SFC calculated from wells plated at 3 Â 10 4 cells per well was included in the calculation of SFC only if N10 spots per well were observed.
SIV-specific CTL assays
CTL activity was measured as previously described (Johnson et al., 1997) . Briefly, PBMC were isolated from CPT Vacutainer tubes centrifuged at 2800 rpm for 30 min at room temperature and then suspended at 2 Â 10 6 cells/ml in RPMI 1640 medium (Life Technologies, Gaithersburg, MD) supplemented with 10% FBS (Sigma, St. Louis, MO), 10 mM HEPES, 2 mM l-glutamine, 50 IU of penicillin/ml, and 50 Ag of streptomycin/ml (R-10). Herpesvirus papio-transformed B cell lines (B-LCL) were prepared from PBMC as described previously (Johnson et al., 1997) and propagated in RPMI 1640 medium supplemented with 20% FBS. Autologous B-LCL infected with control vaccinia virus NYCBH or a recombinant vaccinia virus (vAbt388; provided by D. Panicali, Therion Biologics, Cambridge, Mass.) containing the SIVmac251 gag and pol genes and the SIVmac 239 env gene were used. After a 90-min incubation with vaccinia virus, cells were washed once and used as stimulators. The PBMC were mixed with stimulators in R-10 at a concentration of 2 Â 10 6 /ml at a responder to stimulator ratio of 10:1 and incubated at 37 8C in a 5% CO 2 incubator. Cell cultures were fed with R-10 medium twice a week and recombinant human IL-2 (final concentration 20 U/ml) was added to the medium after 4-5 days. CTL assays were performed 10-14 days after stimulation. Target cells consisted of autologous B-LCL infected with individual recombinant vaccinia viruses expressing the SIV Gag derived from SIVmac251, or the Gag and Pol proteins derived from the SIVsmH4 clone. SIVsmH4, which is more closely related to the SIVsmE660 virus than SIVmac239 (Hirsch et al., 1989) , is a molecular clone of SIV derived from a macaque that developed AIDS after being experimentally inoculated with SIV from an asymptomatic sooty mangabey. The unmodified vaccinia virus NYCBH was used as a control. Target cells were infected overnight at a multiplicity of infection of 5-10 PFU/cell and then labeled with 50 ACi 51 Cr (DuPont-NEN, Wilmington, DE)/10 6 cells. Target cells (10 4 cells/well) were dispensed in triplicate for each E/T cell ratio into 96-well U-bottom plates (Costar, Cambridge, MA). Cold target inhibition was used in all assays to decrease background lysis. Cold targets consisted of unlabeled autologous B-LCL that had been infected with the control vaccinia virus NYCBH and were used at a cold/ hot target ratio of 15:1. Chromium release was assayed after a 5-h incubation at 37 8C in a 5% CO 2 incubator. Plates were spun at 1000 rpm for 10 min at 4 8C, after which 30 Al of supernatant was harvested from each well onto wells of a LumaPlate-96 (Packard) and allowed to dry overnight. Emitted radioactivity was measured in a 1450 MicroBeta Plus Liquid Scintillation Counter (Wallac, Turku, Finland). Spontaneous release was measured from wells containing only target cells and medium. Maximum release was measured from wells containing target cells and 0.1% Triton X-100 (Sigma). The percent cytotoxicity was calculated as follows: ((test release À spontaneous release) / (maximum release À spontaneous release)) Â 100%. Spontaneous release of target cells was b25% in all assays.
Measurement of humoral responses
Plasma samples were analyzed for reactivity to SIV envelope glycoproteins (gp120 and gp41) in a concanavalin A (ConA) ELISA as described previously (Cole et al., 1997) . Briefly, endpoint titers to viral envelope glycoproteins are reported as the last serial 2-fold dilution with an optical density twice that of uninfected monkey serum, or an optical density of 0.1, whichever value was greater.
Neutralizing antibodies were measured in a CEMx174 cell-killing assay as described . Titers of neutralizing antibodies are reported as the reciprocal plasma dilution at which 50% of cells were protected from virus-induced killing as measured by neutral red uptake. A 50% reduction in cell-killing corresponds to an approximate 90% reduction in viral Gag antigen synthesis in this assay . Assays stocks of virus were generated in human PBMC (SIV-mac239/nef-open), CEMx174 cells (SIVsmE660) and H9 cells (TCLA SIVmac251). Plasma samples were heatinactivated for 1 h at 56 8C prior to assay.
